JD Supra: Mergers

SEPTEMBER 6, 2023

For years, the antitrust enforcement agencies have indicated their antipathy toward resolving competition issues in proposed mergers by entering into consent decrees that prohibit certain conduct, rather than stopping the merger entirely or fixing the competition issues through divestitures. By: Mintz - Antitrust Viewpoints

Mergers 172

Mergers Pharmaceutical IT 172

Global Newswire by Notified: M&A

OCTOBER 4, 2024

OnKure Announces Closing of Merger with Reneo Pharmaceuticals.

Pharmaceutical 49

Pharmaceutical Mergers 49

Global Newswire by Notified: M&A

MARCH 20, 2024

Nika Pharmaceuticals, Inc. OTCMKTS: NKPH) announces its merger with Nika BioTechnology, Inc., effective as of March 1, 2024.

Pharmaceutical 89

Pharmaceutical Mergers IT 89

JD Supra: Mergers

JULY 10, 2024

Cephalon, Inc., 2018-0075-SG (Del. 30, 2024) - Stockholder representatives of an acquired corporation brought claims alleging that defendants had failed to use contractually-required commercially reasonable efforts to commercialize an acquired drug asset for a particular use. By: Morris James LLP

Pharmaceutical 161

Pharmaceutical Mergers Corporation 161

JD Supra: Mergers

OCTOBER 2, 2024

The UK DMCC forms part of a global trend to focus merger review increasingly on vertical concerns and concerns about eliminating nascent competition, including by so-called “killer acquisitions” of firms perceived as future competitive threats. The reforms are particularly relevant to the technology and pharmaceutical.

Mergers and Acquisitions 155

Mergers and Acquisitions Pharmaceutical Mergers Acquisitions 155

Global Newswire by Notified: M&A

MAY 13, 2024

Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology

Mergers 53

Mergers Pharmaceutical Portfolio 53

Global Newswire by Notified: M&A

JULY 9, 2024

ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger

Mergers 61

Mergers Pharmaceutical Stock 61

JD Supra: Mergers

MAY 26, 2023

On May 17, 2023, the Federal Trade Commission (FTC) challenged Amgen Inc.’s s (Amgen) proposed acquisition of Horizon Therapeutics plc (Horizon). The complaint is significant in three respects. By: Wilson Sonsini Goodrich & Rosati

Mergers 130

Mergers Pharmaceutical Trading Acquisitions 130

Global Newswire by Notified: M&A

OCTOBER 6, 2023

PRESIDIO PROPERTY TRUST ANNOUNCES CLOSING OF MERGER OF ITS SPONSORED SPAC MURPHY CANYON ACQUISITION CORP NOW TRADING AS CONDUIT PHARMACEUTICALS.

Pharmaceutical 40

Pharmaceutical Mergers and Acquisitions Mergers Trading 40

Global Newswire by Notified: M&A

OCTOBER 2, 2024

– Combined company to trade on Nasdaq under ticker “OKUR” – Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., 02, 2024 (GLOBE.

Pharmaceutical 45

Pharmaceutical Mergers Stock Trading 45

Global Newswire by Notified: M&A

AUGUST 15, 2023

Reverse Stock Split Merger on Track to Close on August 16, 2023 Approximately 71% of Stockholders Voted in Favor of the Transaction Diffusion Announces 1-for-1.5

Mergers 40

Mergers Pharmaceutical Stock 40

Global Newswire by Notified: M&A

SEPTEMBER 11, 2024

ANI and Alimera Scheduled the Closing for September 16, 2024 ANI and Alimera Scheduled the Closing for September 16, 2024

Pharmaceutical 56

Pharmaceutical Mergers 56

JD Supra: Mergers

SEPTEMBER 27, 2024

On September 11-12, we had the pleasure of attending the LSX World Congress USA in Boston, where leaders discussed the challenges and opportunities of M&A and partnerships in the pharmaceutical sector. By: A&O Shearman

Pharmaceutical 161

Pharmaceutical M&A 161

Global Newswire by Notified: M&A

JULY 23, 2024

The Company reports steady progress in its due diligence efforts and, contingent upon meeting all regulatory requirements, anticipates completing the Proposed Transaction by the end of August 2024.

Mergers 40

Mergers Pharmaceutical Medical IT 40

JD Supra: Mergers

NOVEMBER 7, 2024

Alexion Pharmaceuticals, Inc., In Shareholder Representative Services LLC v. the Delaware Court of Chancery addressed an earnout dispute, holding that a buyer violated its contract with the seller by failing to use “commercially reasonable efforts” to meet the contractual milestones that would entitle the seller to a hefty earnout payment.

Pharmaceutical 161

Pharmaceutical IT 161

JD Supra: Mergers

OCTOBER 30, 2024

Alexion Pharmaceuticals, Inc. Johnson & Johnson, the court awarded nearly $1 billion in damages for breach of contract to the target company’s stockholders, while the court in Shareholder Representative Services LLC v. will announce its damages determination. By: Mayer Brown

Pharmaceutical 167

Pharmaceutical IT 167

JD Supra: Mergers

APRIL 18, 2024

On March 26, 2024, Skadden hosted a discussion on key developments in antitrust enforcement in the pharmaceuticals and life sciences sectors. By: Skadden, Arps, Slate, Meagher & Flom LLP

Pharmaceutical 172

Pharmaceutical 172

Global Newswire by Notified: M&A

JULY 27, 2024

Nasdaq: ALIM ) , relating to its proposed merger with ANI Pharmaceuticals, Inc. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50

M&A 45

M&A Mergers Pharmaceutical Shares 45

JD Supra: Mergers

SEPTEMBER 4, 2024

August 01, 2024: SEAM Group, a B2B business products and services company that provides safety, reliability, maintenance, and enterprise asset management services in the hospitality, food processing, and pharmaceutical industries, was acquired by ABB for an undisclosed amount.

M&A 167

M&A Hospitality Asset Management Pharmaceutical 167

JD Supra: Mergers

MAY 15, 2024

Bass, Berry & Sims brought a team of four attorneys from our Specialty Pharmacy & Pharmaceuticals and 340B Program Services practice groups to join the fun. Asembia’s 20th Annual Specialty Pharmacy Summit once again brought investors and operators in the specialty pharmacy ecosystem to Las Vegas for learning sessions and networking.

Pharmaceutical 172

Pharmaceutical Investors 172

JD Supra: Mergers

MARCH 27, 2024

designs and produces solutions for the biopharmaceutical, pharmaceutical and medical device markets and aerospace industries. New Mountain Capital will sell ILC Dover to Ingersoll Rand for about $2.3 billion, according to industry reports. ILC, founded in 1947 and based in Frederica, Del., By: McGuireWoods LLP

Private Equity 155

Private Equity Pharmaceutical Healthcare Medical 155

JD Supra: Mergers

JULY 10, 2024

Among these are two cross-agency Requests for Information (RFIs) about anticompetitive transactions, an online portal to enable anyone to report anticompetitive business practices, a new Department of Justice (DOJ) task force and a new Federal Trade Commission (FTC) investigation into certain Teva Pharmaceuticals’ patent.

Pharmaceutical 167

Pharmaceutical Government Trading Business 167

JD Supra: Mergers

JULY 24, 2023

While the two companies evidently have some history together, this new deal is reportedly tied to Phillip Morris’ interest in acquiring Syqe’s metered-dose, pharmaceutical-grade inhaler that dispenses precise doses of medical cannabis to patients. By: Bradley Arant Boult Cummings LLP

Medical 246

Medical Pharmaceutical 246

JD Supra: Mergers

APRIL 23, 2024

We were fortunate to have a mix of expert perspectives at the table, representing large pharmaceutical companies, investors, By: Mintz Asset Sale,” with business development leaders from GSK, Johnson & Johnson, Locust Walk, and Astria Therapeutics.

Pharmaceutical 167

Pharmaceutical M&A Sale Investors 167

JD Supra: Mergers

JANUARY 22, 2024

Morgan Healthcare Conference in San Francisco, which also saw the announcement of major acquisitions by large players in the pharmaceutical space. The timing of the announcement coincided with the start of the 42nd Annual J.P. By: Knobbe Martens

Pharmaceutical 177

Pharmaceutical Healthcare Corporation Equities 177

JD Supra: Mergers

JANUARY 26, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022), total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. By: Cooley LLP

M&A 167

M&A Pharmaceutical Business 167

JD Supra: Mergers

FEBRUARY 5, 2024

The European Commission (EC) has published its latest report on competition enforcement in medicines and medical products. Key takeaways are that: EU and Member State authorities imposed multiple material antitrust fines from 2018-2022, totalling approx. EUR780 million. By: Allen & Overy LLP

Pharmaceutical 167

Pharmaceutical Medical IT 167

JD Supra: Mergers

DECEMBER 1, 2023

To that end, the DOJ recently announced its decision to decline to prosecute Lifecore Biomedical, a pharmaceutical and medical device manufacturer, despite evidence that employees of Lifecore’s former US subsidiary bribed Mexican government officials in violation of the Foreign Corrupt Practices Act.

M&A 167

M&A Pharmaceutical Medical Manufacturing 167

JD Supra: Mergers

MAY 23, 2023

ACN, based in Dallas, is a clinical site platform serving patients, pharmaceutical sponsors and contract research organizations. Amulet Capital Partners has announced it has acquired Alliance Clinical Network (ACN). By: McGuireWoods LLP

Private Equity 130

Private Equity Pharmaceutical Healthcare Equities 130

Global Newswire by Notified: M&A

APRIL 11, 2024

Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it signed a merger agreement (the “Agreement”) with AutoMax Motors Ltd.

Pharmaceutical 53

Pharmaceutical Mergers IT 53

Global Newswire by Notified: M&A

NOVEMBER 6, 2024

billion.

Capital 75

Capital Pharmaceutical Manufacturing Funds 75

Shearman & Sterling

JANUARY 8, 2019

. ("Ception") against pharmaceutical company Cephalon, Inc. ("Cephalon"), which acquired Ception, alleging violations of an earn-out provision in their merger agreement. The Court also dismissed an implied covenant claim against Cephalon and tortious interference claims against Teva Pharmaceutical Industries Ltd.

Pharmaceutical 52

Pharmaceutical Mergers Medical IT 52

Devensoft

MAY 25, 2023

Corporate restructuring can be a game-changer for any organization, whether it’s a merger, acquisition, or any other strategic move. Understanding merger vs acquisition Mergers and acquisitions (M&A) are two of the most common forms of corporate restructuring.

Corporation 52

Corporation Mergers Mergers and Acquisitions Acquisitions 52

The Guardian: Mergers & Acquisitions

OCTOBER 21, 2024

Move follows fears over jobs and control when private equity firm CD&R entered talks to buy Opella for €16bn The French government is to take a stake in the pharmaceutical company Sanofi’s consumer healthcare division to try to quell a backlash as the US private equity firm Clayton, Dubilier & Rice enters talks to buy the unit for €16bn (£13.3bn). (..)

Private Equity 63

Private Equity Pharmaceutical Sale Equities 63

Solganick & Co.

SEPTEMBER 2, 2024

September 2, 2024 – The software mergers and acquisitions (M&A) marketplace has been bustling with activity in the first half of 2024, reflecting the sector’s robust growth and strategic consolidations. per share in cash in a transaction that values the Company at approximately $1.25

Mergers and Acquisitions 52

Mergers and Acquisitions Acquisitions Mergers M&A 52

JD Supra: Mergers

MAY 25, 2023

Our prior updates covered how FTC enforcement activity largely proceeded “as usual” during 2022 in the life sciences industry, with large pharmaceutical players buying or licensing promising, but still risky, assets from clinical- or preclinical-stage companies.

Pharmaceutical 130

Pharmaceutical 130

The Guardian: Mergers & Acquisitions

MARCH 19, 2024

The Anglo-Swedish company struck an agreement to acquire Fusion Pharmaceuticals, which is developing next-generation radioconjugates that offer an alternative to chemotherapy and radiotherapy.

Pharmaceutical 95

Pharmaceutical Portfolio Acquisitions Business 95